Should Cboe’s (CBOE) Plan to Launch Continuous Bitcoin and Ether Futures Prompt Investor Reassessment?

• On September 9, 2025, Cboe Global Markets announced plans to launch Cboe Continuous futures for bitcoin and ether on its U.S. futures exchange, pending regulatory review.
• This move introduces single, long-dated, cash-settled contracts with daily spot price alignment, aiming to simplify digital asset exposure and risk management for U.S. traders.
• We'll explore how the introduction of Cboe Continuous futures in digital assets could influence the long-term investment outlook for the company.

AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Cboe Global Markets Investment Narrative Recap

The core belief for Cboe Global Markets shareholders centers on the company’s ability to drive sustainable growth by expanding its product suite while managing industry and competitive risks. The launch of Cboe Continuous futures for bitcoin and ether could support Cboe’s position as a diversified exchange leader, but the primary short-term catalyst remains maintaining robust transaction-based revenue, with the biggest risk still tied to dependence on its S&P index options franchise; the new digital assets products do not materially reduce this concentration risk yet. Of the company’s recent announcements, the successful migration of Cboe Digital Exchange futures to the Cboe Futures Exchange stands out. By consolidating U.S. futures products on one platform prior to the introduction of Continuous futures, Cboe has potentially strengthened operational efficiency and set the stage for further growth – lining up with the company’s ongoing pursuit of stable transaction revenue, which is crucial against the backdrop of sector competition and shifting market structures. In contrast, investors should also be aware of the outsized influence of Cboe’s partnership with S&P as…

Read the full narrative on Cboe Global Markets (it's free!)

Cboe Global Markets is projected to reach $2.6 billion in revenue and $1.1 billion in earnings by 2028. This outlook assumes a 16.9% annual decline in revenue, but an increase in earnings of about $204 million from the current $896.3 million.

Uncover how Cboe Global Markets' forecasts yield a $247.47 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members set Cboe Global Markets’ fair value across a striking US$41.96 to US$247.47, reflecting ten varied forecasts. While the most recent catalyst targets digital asset growth, the largest risk remains future S&P index contract negotiations, influencing both confidence and caution across perspectives.

Explore 10 other fair value estimates on Cboe Global Markets - why the stock might be worth as much as 6% more than the current price!

Build Your Own Cboe Global Markets Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Cboe Global Markets research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Cboe Global Markets research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cboe Global Markets' overall financial health at a glance.

Seeking Other Investments?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• These 9 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com